CN101574320A - Intestinal protection medicament and preparation method thereof - Google Patents
Intestinal protection medicament and preparation method thereof Download PDFInfo
- Publication number
- CN101574320A CN101574320A CNA2008100255842A CN200810025584A CN101574320A CN 101574320 A CN101574320 A CN 101574320A CN A2008100255842 A CNA2008100255842 A CN A2008100255842A CN 200810025584 A CN200810025584 A CN 200810025584A CN 101574320 A CN101574320 A CN 101574320A
- Authority
- CN
- China
- Prior art keywords
- bismuth subsalicylate
- lyophilizing
- principal agent
- agent
- handled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a bismuth subsalicylate dispersing tablet and a preparation method thereof. The bismuth subsalicylate dispersing tablet is convenient and flexible to take, has an excellent taste, not only can be drunk after being dissolved in water, but also can be directly swallowed or chewed and sucked. The bismuth subsalicylate dispersing tablet as a gastrointestinal medicament can be rapidly disintegrated, has a favorable taste without a sandy feedling and costs little effect for old people, children or patients troublesome in swallowing the medicament. The invention has simple manufacture technology and unique prescription, can fully exert the efficacy of the medicament, is convenient to take and has favorable popularization prospects.
Description
Technical field:
The present invention relates to intestinal protective agent medicine bismuth subsalicylate dispersible tablet and preparation method thereof.
Background technology:
Bismuth subsalicylate (C
7H
5BiO
4) claim 2 hydroxybenzoic acid bismuth (+3 valency) salt again, be a kind of basic salt, this product is as a kind of intestinal protective agent abroad clinically.Bismuth subsalicylate has: be covered in mucosa surface, the protection gastric mucosa reduces the pessimal stimulation of stomach; The secretion inhibitor effect; Absorption bacteriocin (as the toxin of colon bacillus generation or the enterotoxin of vibrio cholera generation) reaches the direct antibacterial activity to pathogenic microbes.
At present bismuth subsalicylate has become one of choice drug of the gastroenteropathys such as stomach discomfort that treatment diarrhoea, heartburn, nauseating, dyspepsia, eating and drinking too much at one meal causes abroad on the market, and quilt is recorded in American Pharmacopeia 23,24 editions.
Oral solid formulation is one of pharmaceutical dosage form of using always, but some tablet and capsule be because volume need be obeyed multi-disc (grain) more greatly or once, special gives always, the patient of children and dysphagia brought trouble.Though the liquid preparation taking convenience has many medicines unstable in water, also has packing, transportation, stores inconvenience etc.Dispersible tablet is a kind of novel form of developing in recent years, the good reputation that " Peroral solid dosage form liquid " is arranged, its key component is medicine and at least a disintegrating agent and meets water and form compatibility such as full-bodied swelling adjuvant and form, it integrates the advantage of tablet and liquid preparation, not only solved the complexity on liquid preparation, the drop production technology, also solved simultaneously the inconvenience in packing, storage, the transportation, in addition on curative effect also can to liquid preparation such as oral liquid quite or similar.The characteristics of dispersible tablet are to meet the rapid disintegrate of water to become fine particle, and uniform particles is disperseed, and compares with effervescent tablet to have lot of advantages, does not have taboo as prescription compatibility of medicines, does not need effervescent and water soluble adjuvant.After insoluble drug made dispersible tablet, can obviously improve the dissolving out capability of medicine, for the pharmaceutics basis has been established in the raising of biological effectiveness.In addition, dispersible tablet is taken more convenient, can directly swallow or disperse back and fruit juice, milk and clothes in water, also can chew or contain to suck and take, and instructions of taking is various.Especially the patient who is fit to old, children and dysphagia, and can characteristics such as produce with conventional tablet production technology and equipment, be a kind of good novel form.Research to dispersible tablet has become at present the focus of preparation research both at home and abroad.
Summary of the invention:
It is flexible to the purpose of this invention is to provide a kind of taking convenience, and mouthfeel is good, both can disperse the back oral in water, and also can directly swallow or chew contains the bismuth subsalicylate dispersible tablet of sucking, and mouthfeel is good and preparation method thereof.
Active constituents of medicine is the intestinal protective agent bismuth subsalicylate, is a kind of basic salt, has antibiotic, antiendotoxin and secretion inhibitor effect, reduces gathering of intestinal liquid, shortens the diarrheal course of disease.It is as intestinal protective agent; be the most frequently used medicines of disease such as treatment diarrhoea, gastrointestinal upset abroad; it also can alleviate and treat symptoms such as child and child's functional dyspepsia and diarrhoea safely and effectively in the corresponding symptom treatment that generally is used to be grown up.
Because the principal agent composition is the not dissolved salt of trivalent bismuth and Salicylate, therefore in order to eliminate its grittiness in mouth, the present invention has adopted principal agent has been handled through freeze-drying.The principle that freeze-drying is handled is to be frozen into solid rapidly after medicine is made suspension, again under vacuum condition, from frozen state without the liquid and dewatered a kind of drying means that directly distils.The lyophilization product generally all is short texture, and interior rich small spaces can absorb water dissolution rapidly.By accelerating chilling rate, some medicine crystalline lattice arrangement in recrystallization process is changed, the crystalline particle particle diameter is reduced, increase specific surface area, or making higher metastable state of some medicine produce power or amorphous state, the two all makes the dissolubility of medicine and dissolution velocity increase.
The prescription that the raw material lyophilizing is handled comprises principal agent and substrate, adds one or more surfactants in the medicine suspendible, and surfactant has sodium laurylsulfate, lecithin, tween and span etc.For medicine is evenly distributed, can add a certain amount of long-chain polymer substance, as polypeptide class (adding gelatin or dehydration gelatin) in suspension; Polysaccharide (dextran, glucosan, mannitol and starch etc.); Glue class (adding arabic gum, xanthan gum, natural gum), cellulose family, alginates, polyvinyl alcohol etc. keep minute bubbles simultaneously; Also can add other adjuvant according to difference prescription needs, commonly used have coloring agent (iron oxides), antiseptic, antioxidant and a spice etc.
In the prescription of bismuth subsalicylate dispersible tablet, excipient is selected from microcrystalline Cellulose and mannitol, and microcrystalline cellulose have the effect that improves drug flow and promote disintegrate, mannitol good water solubility, just melt in the mouth, little sweet and cool taste; Disintegrating agent is selected from crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose or their mixture, and disintegrating agent can adopt interior addition, outer addition or both bonded methods; Draw humectant and select sodium lauryl sulphate for use; Binding agent is selected from polyvinylpyrrolidone K90 or polyvinylpyrrolidone K30; Lubricant is selected from magnesium stearate, silicon dioxide, Pulvis Talci.The tablet that forms can be uniformly dispersed in 50 seconds.The present invention is big than the sheet hardness of freeze-dried instant sheet, can simplify packing, and convenient transportation reduces cost.
With the bismuth subsalicylate is principal agent, and drug content is the 262mg/ sheet, and other composition for the prescription of adjuvant weight share preparation dispersible tablet is:
Except as otherwise noted, the percent that is adopted among the present invention is percetage by weight.
B, microcrystalline Cellulose 27 ~ 51%
C, polyvinylpyrrolidone K90/K30 2.5 ~ 3.5%
D, crospolyvinylpyrrolidone 7 ~ 14%
E, low-substituted hydroxypropyl cellulose 14 ~ 17%
F, cross-linking sodium carboxymethyl cellulose 9 ~ 17%
G, sodium lauryl sulphate 3 ~ 8 ‰
H, magnesium stearate 9 ‰
I, silicon dioxide 2% ~ 3%
J, Pulvis Talci 2%
Concrete preparation method is as described below:
Earlier the principal agent bismuth subsalicylate being carried out lyophilizing handles.The prescription that substrate is handled in the bismuth subsalicylate lyophilizing is:
2% ~ 5% of lecithin principal agent amount
2% ~ 4% of sodium laurylsulfate principal agent amount
3% ~ 20% of gelatin principal agent amount
3% ~ 15% of xanthan gum principal agent amount
3% ~ 12% of HPMC principal agent amount
Bismuth subsalicylate is suspended in the purified water, adds the substrate adjuvant of recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of bismuth subsalicylate, standby.
Microcrystalline Cellulose, polyvinylpyrrolidone K90/K30 pulverize separately are crossed 100 mesh sieves, take by weighing the bismuth subsalicylate and the microcrystalline Cellulose mix homogeneously of recipe quantity, the polyvinylpyrrolidone K90/K30, crospolyvinylpyrrolidone, the low-substituted hydroxypropyl cellulose that add recipe quantity again mix, and mixing sieves; Sodium lauryl sulphate is dissolved in an amount of 50% alcohol, adds in the said mixture and make soft material, cross 24 mesh sieves, in 50 ~ 60 ℃ of dryings 6 ~ 8 hours, 20 eye mesh screen granulate; Mix magnesium stearate and 2% silicon dioxide eventually, carry out the intermediate content detection into particle weight 9 ‰; Tabletting promptly gets the bismuth subsalicylate dispersible tablet.
The present invention is as gastrointestinal drug disintegrate and have good mouthfeel and do not have grittiness rapidly, to some old peoples, child or swallow the inconvenient patient of medicine when taking medicine obstacle less.When taking, can in water, disperse the back oral, also can directly swallow or chew to contain and suck.Dispersible tablet of the present invention is in the water of room temperature, and all disintegrates, dispersion in three minutes are by No. 2 sieves.This dosage form can be used conventional tablet pharmaceutical equipment to produce and use the pressing process preparation, avoids overlapping investment.Its processing technology is simple, and prescription is unique, can give full play to drug effect and conveniently takes, and has the excellent popularization prospect.
The specific embodiment:
Implement 1 example:
The lyophilizing of principal agent is handled:
Bismuth subsalicylate 300g
Lecithin 10g
Gelatin 15g
HPMC 27g
Bismuth subsalicylate is suspended in the purified water, adds the substrate adjuvant of recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of bismuth subsalicylate, standby.
With the bismuth subsalicylate is principal agent, and other composition is that the prescription of adjuvant preparation bismuth subsalicylate dispersible tablet is:
Lyophilizing is handled principal agent and is equivalent to bismuth subsalicylate 262g
Microcrystalline Cellulose 160g
Crospolyvinylpyrrolidone 60g
Low-substituted hydroxypropyl cellulose 80g
Polyvinylpyrrolidone (K30) 20g
Sodium lauryl sulphate 2g
Magnesium stearate 9 ‰
Silicon dioxide 3%
50% ethanol Q.S
Make 1000
Concrete preparation method is as described below:
Microcrystalline Cellulose, polyvinylpyrrolidone K90/K30 pulverize separately are crossed 100 mesh sieves, bismuth subsalicylate and microcrystalline Cellulose mix homogeneously are handled in the lyophilizing that takes by weighing recipe quantity, the polyvinylpyrrolidone K30,40g crospolyvinylpyrrolidone, the low-substituted hydroxypropyl cellulose that add recipe quantity again mix, and mixing sieves; Sodium lauryl sulphate is dissolved in an amount of 50% ethanol, adds in the said mixture and make soft material, cross 24 mesh sieves, in 50 ~ 60 ℃ of dryings 6 ~ 8 hours, 24 eye mesh screen granulate; Mix crospolyvinylpyrrolidone eventually, carry out the intermediate content detection into magnesium stearate and 3% silicon dioxide and the surplus of particle weight 9 ‰; Tabletting, promptly.
Implement 2 examples:
The lyophilizing of principal agent is handled:
Bismuth subsalicylate 300g
Lecithin 10g
Gelatin 15g
HPMC 27g
Bismuth subsalicylate is suspended in the purified water, adds the substrate adjuvant of recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of bismuth subsalicylate, standby.
With the bismuth subsalicylate is principal agent, and other composition is that the prescription of adjuvant preparation bismuth subsalicylate dispersible tablet is:
Lyophilizing is handled principal agent and is equivalent to bismuth subsalicylate 262g
Microcrystalline Cellulose 200g
Crospolyvinylpyrrolidone 80g
Polyvinylpyrrolidone (K30) 20g
Sodium lauryl sulphate 2g
Magnesium stearate 9 ‰
Silicon dioxide 3%
50% ethanol Q.S
Make 1000
Concrete preparation method is as described below:
Microcrystalline Cellulose, polyvinylpyrrolidone K90/K30 pulverize separately are crossed 100 mesh sieves, bismuth subsalicylate and microcrystalline Cellulose mix homogeneously are handled in the lyophilizing that takes by weighing recipe quantity, the polyvinylpyrrolidone K90/K30, the 40g crospolyvinylpyrrolidone that add recipe quantity again mix, and mixing sieves; Sodium lauryl sulphate is dissolved in an amount of 50% ethanol, adds in the said mixture and make soft material, cross 24 mesh sieves, in 50 ~ 60 ℃ of dryings 6 ~ 8 hours, 24 eye mesh screen granulate; Mix crospolyvinylpyrrolidone eventually, carry out the intermediate content detection into magnesium stearate and 3% silicon dioxide and the surplus of particle weight 9 ‰; Tabletting, promptly.
Implement 3 examples:
The lyophilizing of principal agent is handled:
Bismuth subsalicylate 300g
Sodium laurylsulfate 8g
Gelatin 15g
HPMC 27g
Bismuth subsalicylate is suspended in the purified water, adds the substrate adjuvant of recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of bismuth subsalicylate, standby.
With the bismuth subsalicylate is principal agent, and other composition is that the prescription of adjuvant preparation bismuth subsalicylate dispersible tablet is: it comprises by the following weight proportion raw material makes:
Lyophilizing is handled principal agent and is equivalent to bismuth subsalicylate 262g
Microcrystalline Cellulose 200g
Low-substituted hydroxypropyl cellulose 80g
Crospolyvinylpyrrolidone 40g
Polyvinylpyrrolidone (K30) 20g
Sodium lauryl sulphate 2g
Magnesium stearate 9 ‰
Silicon dioxide 2%
50% ethanol Q.S
Make 1000
Microcrystalline Cellulose, polyvinylpyrrolidone K90/K30 pulverize separately are crossed 100 mesh sieves, bismuth subsalicylate and microcrystalline Cellulose mix homogeneously are handled in the lyophilizing that takes by weighing recipe quantity, the polyvinylpyrrolidone K30, low-substituted hydroxypropyl cellulose, the crospolyvinylpyrrolidone that add recipe quantity again mix, and mixing sieves; Sodium lauryl sulphate is dissolved in an amount of 50% alcohol, adds in the said mixture and make soft material, cross 24 mesh sieves, in 50 ~ 60 ℃ of dryings 6 ~ 8 hours, 24 eye mesh screen granulate; Mix magnesium stearate and 2% silicon dioxide eventually, carry out the intermediate content detection into particle weight 9 ‰; Tabletting, promptly.
Implement 4 examples:
The lyophilizing of principal agent is handled:
Bismuth subsalicylate 300g
Sodium laurylsulfate 8g
Gelatin 15g
HPMC 27g
Bismuth subsalicylate is suspended in the purified water, adds the substrate adjuvant of recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of bismuth subsalicylate, standby.
With the bismuth subsalicylate is principal agent, and other composition is that the prescription of adjuvant preparation bismuth subsalicylate dispersible tablet is: it comprises by the following weight proportion raw material makes:
Lyophilizing is handled principal agent and is equivalent to bismuth subsalicylate 262g
Microcrystalline Cellulose 250g
Crospolyvinylpyrrolidone 40g
Polyvinylpyrrolidone (K30) 20g
Sodium lauryl sulphate 2g
Magnesium stearate 9 ‰
Silicon dioxide 2%
50% ethanol Q.S
Make 1000
Microcrystalline Cellulose, polyvinylpyrrolidone K90/K30 pulverize separately are crossed 100 mesh sieves, bismuth subsalicylate and microcrystalline Cellulose mix homogeneously are handled in the lyophilizing that takes by weighing recipe quantity, the polyvinylpyrrolidone K30, low-substituted hydroxypropyl cellulose, the crospolyvinylpyrrolidone that add recipe quantity again mix, and mixing sieves; Sodium lauryl sulphate is dissolved in an amount of 50% ethanol, adds in the said mixture and make soft material, cross 24 mesh sieves, in 50 ~ 60 ℃ of dryings 6 ~ 8 hours, 24 eye mesh screen granulate; Mix magnesium stearate and 2% silicon dioxide eventually, carry out the intermediate content detection into particle weight 9 ‰; Tabletting, promptly.
Implement 5 examples:
The lyophilizing of principal agent is handled:
Bismuth subsalicylate 300g
Sodium laurylsulfate 8g
Xanthan gum 10g
HPMC 20g
Bismuth subsalicylate is suspended in the purified water, adds the substrate adjuvant of recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of bismuth subsalicylate, standby.
With the bismuth subsalicylate is principal agent, and other composition is that the prescription of adjuvant preparation bismuth subsalicylate dispersible tablet is: it comprises by the following weight proportion raw material makes:
Lyophilizing is handled principal agent and is equivalent to bismuth subsalicylate 262g
Microcrystalline Cellulose 200g
Low-substituted hydroxypropyl cellulose 100g
Polyvinylpyrrolidone (K90) 10g
Sodium lauryl sulphate 2g
Magnesium stearate 9 ‰
Silicon dioxide 3%
50% ethanol Q.S
Make 1000
Microcrystalline Cellulose, polyvinylpyrrolidone K90/K30 pulverize separately are crossed 100 mesh sieves, bismuth subsalicylate and microcrystalline Cellulose mix homogeneously are handled in the lyophilizing that takes by weighing recipe quantity, the polyvinylpyrrolidone K90, the low-substituted hydroxypropyl cellulose that add recipe quantity again mix, and mixing sieves; Sodium lauryl sulphate is dissolved in an amount of 50% ethanol, adds in the said mixture and make soft material, cross 24 mesh sieves, in 50～60 ℃ of dryings 6～8 hours, 24 eye mesh screen granulate; Mix magnesium stearate and 3% silicon dioxide eventually, carry out the intermediate content detection into particle weight 9 ‰; Tabletting, promptly.
Implement 6 examples:
The lyophilizing of principal agent is handled:
Bismuth subsalicylate 300g
Sodium laurylsulfate 8g
Xanthan gum 10g
HPMC 20g
Bismuth subsalicylate is suspended in the purified water, adds the substrate adjuvant of recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of bismuth subsalicylate, standby.
With the bismuth subsalicylate is principal agent, and other composition is that the prescription of adjuvant preparation bismuth subsalicylate dispersible tablet is: it comprises by the following weight proportion raw material makes:
Lyophilizing is handled principal agent and is equivalent to bismuth subsalicylate 262g
Microcrystalline Cellulose 300g
Polyvinylpyrrolidone (K90) 10g
Sodium lauryl sulphate 5g
Magnesium stearate 9 ‰
Silicon dioxide 2%
50% ethanol Q.S
Make 1000
Microcrystalline Cellulose, polyvinylpyrrolidone K90/K30 pulverize separately are crossed 100 mesh sieves, and bismuth subsalicylate and microcrystalline Cellulose mix homogeneously are handled in the lyophilizing that takes by weighing recipe quantity, and the polyvinylpyrrolidone K90 that adds recipe quantity again mixes, and mixing sieves; Sodium lauryl sulphate is dissolved in an amount of 50% ethanol, adds in the said mixture and make soft material, cross 24 mesh sieves, in 50～60 ℃ of dryings 6～8 hours, 24 eye mesh screen granulate; Mix magnesium stearate and 2% silicon dioxide eventually, carry out the intermediate content detection into particle weight 9 ‰; Tabletting, promptly.
Implement 7 examples:
The lyophilizing of principal agent is handled:
Bismuth subsalicylate 300g
Lecithin 10g
Xanthan gum 10g
HPMC 20g
Bismuth subsalicylate is suspended in the purified water, adds the substrate adjuvant of recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of bismuth subsalicylate, standby.
With the bismuth subsalicylate is principal agent, and other composition is that the prescription of adjuvant preparation bismuth subsalicylate dispersible tablet is: it comprises by the following weight proportion raw material makes:
Lyophilizing is handled principal agent and is equivalent to bismuth subsalicylate 262g
Microcrystalline Cellulose 200g
Cross-linking sodium carboxymethyl cellulose 80g
Polyvinylpyrrolidone (K30) 20g
Sodium lauryl sulphate 2g
Magnesium stearate 9 ‰
Silicon dioxide 3%
50% ethanol Q.S
Make 1000
Concrete preparation method is as described below:
Microcrystalline Cellulose, polyvinylpyrrolidone K90/K30 pulverize separately are crossed 100 mesh sieves, bismuth subsalicylate and microcrystalline Cellulose mix homogeneously are handled in the lyophilizing that takes by weighing recipe quantity, the polyvinylpyrrolidone K30, the 40g cross-linking sodium carboxymethyl cellulose that add recipe quantity again mix, and mixing sieves; Sodium lauryl sulphate is dissolved in an amount of 50% ethanol, adds in the said mixture and make soft material, cross 24 mesh sieves, in 50～60 ℃ of dryings 6～8 hours, 24 eye mesh screen granulate; Mix cross-linking sodium carboxymethyl cellulose eventually, carry out the intermediate content detection into magnesium stearate and 3% silicon dioxide and the surplus of particle weight 9 ‰; Tabletting, promptly.
Claims (7)
1, intestinal protective agent medicine bismuth subsalicylate dispersible tablet and preparation method thereof, the present invention has adopted principal agent has been handled through freeze-drying.
2, according to claim 1, it is to be frozen into solid rapidly after medicine is made suspension that freeze-drying is handled, again under vacuum condition, from frozen state without the liquid and dewatered a kind of drying means that directly distils.
3, according to claim 1 or 2, the prescription that the raw material lyophilizing is handled comprises principal agent and substrate, adds one or more surfactants in the medicine suspendible.
4, according to claim 3, its surfactant can be sodium laurylsulfate, lecithin, tween and span.
5, according to claim 3, be evenly distributed in suspension in order to make medicine, can add a certain amount of long-chain polymer substance.
6, according to claim 5, the long-chain polymer substance can be polypeptide class (adding gelatin or dehydration gelatin); Polysaccharide (dextran, glucosan, mannitol and starch etc.); Glue class (adding arabic gum, xanthan gum, natural gum), cellulose family, alginates, polyvinyl alcohol etc. keep minute bubbles simultaneously.
7, according to claim 1, its preparation methods steps is as follows:
1. principal agent at first carries out the lyophilizing processing: principal agent is suspended in the purified water, the substrate adjuvant that adds recipe quantity, make suspension, be frozen into solid rapidly, again under vacuum condition, from frozen state without liquid and directly distillation remove moisture, obtain lyophilizing and handle raw material, measure the wherein content of principal agent, standby.
2. with adjuvant pulverize separately sieving for standby, take by weighing the supplementary material of recipe quantity, increase progressively principle, add excipient by equivalent, binding agent, part disintegrating agent and other adjuvant mix; Sodium lauryl sulphate is dissolved in an amount of ethanol, adds in the said mixture and make soft material, sieve dry, granulate; Mix disintegrating agent eventually into magnesium stearate, silicon dioxide, Pulvis Talci lubricant and surplus; Tabletting, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100255842A CN101574320A (en) | 2008-05-08 | 2008-05-08 | Intestinal protection medicament and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100255842A CN101574320A (en) | 2008-05-08 | 2008-05-08 | Intestinal protection medicament and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101574320A true CN101574320A (en) | 2009-11-11 |
Family
ID=41269488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100255842A Pending CN101574320A (en) | 2008-05-08 | 2008-05-08 | Intestinal protection medicament and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101574320A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877036A (en) * | 2012-12-21 | 2014-06-25 | 南京亿华药业有限公司 | Rapid disintegrant preparation composition of bismuth subsalicylate and preparing method thereof |
| CN107105665A (en) * | 2014-10-30 | 2017-08-29 | 上阿尔萨斯大学 | One of bismuth subsalicylate or derivatives thereof as plant medicament purposes |
-
2008
- 2008-05-08 CN CNA2008100255842A patent/CN101574320A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877036A (en) * | 2012-12-21 | 2014-06-25 | 南京亿华药业有限公司 | Rapid disintegrant preparation composition of bismuth subsalicylate and preparing method thereof |
| CN107105665A (en) * | 2014-10-30 | 2017-08-29 | 上阿尔萨斯大学 | One of bismuth subsalicylate or derivatives thereof as plant medicament purposes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101283991B (en) | Orally-disintegrating tablet and manufacturing method thereof | |
| RU2189227C2 (en) | Quickly decomposing, pressed in forms materials and method of their preparing | |
| KR101159617B1 (en) | Tablet quickly disintegrating in oral cavity | |
| MXPA04000223A (en) | Novel substituted benzimidazole dosage forms and method of using same. | |
| KR20030094272A (en) | Tablets quickly disintegrating in oral cavity | |
| JP2000103731A (en) | Rapid disintegrative solid preparation | |
| CN101277721B (en) | Orally disintegrating tablet | |
| CN109893516A (en) | For treating the pharmaceutical composition of helicobacter pylori | |
| CN101461788B (en) | Phloroglucine orally disintegrating tablet and preparation method thereof | |
| CN103656654A (en) | Instant orally-disintegrating tablet and its preparation method | |
| CN102512386A (en) | Amoxicillin or amoxicillin and clavulanate potassium instant chewable tablets for pet and preparation method for same | |
| CN103040773A (en) | Doxycycline metal complex in a solid dosage form | |
| CN101564402A (en) | Rehabilitation new dispersing tablet and preparation method thereof | |
| CN102512402B (en) | Novel preparation of medicine for treating gastric and duodenal ulcers and preparation method thereof | |
| CN101574320A (en) | Intestinal protection medicament and preparation method thereof | |
| CN104435216A (en) | Ephedra and apricot cough relieving traditional Chinese medicine dispersible tablet and preparation method thereof | |
| CN101234094B (en) | Dipyridamole orally disintegrating tablet | |
| CN102018721B (en) | Chewable tablet of calcium carbonate dimeticone and preparation process | |
| CN102872024B (en) | Misoprostol medicine combination used in mouths | |
| CN103877036A (en) | Rapid disintegrant preparation composition of bismuth subsalicylate and preparing method thereof | |
| CN100450470C (en) | Rapid disintegrate tablet in oral and its preparation method | |
| CN102600141B (en) | Dispersible tablet containing amoxicillin and potassium clavulanate | |
| CN102058587A (en) | Solid preparation for treating asthma | |
| JPH11116465A (en) | Rapidly dissolvable preparation and its production | |
| CN102488708B (en) | Magaldrate chewable tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091111 |